Bright Minds Biosciences DRUG
NASDAQ DRUG
$23.45 +0.84 (+3.72%)
At close: Nov 11, 2026 · 4:00 PM EST

Bright Minds Biosciences (DRUG) Receivables - Other (2022 - 2025)

Updated

Bright Minds Biosciences (DRUG) reported Receivables - Other of $113,645 for fiscal Q3 2025 (quarter ended Jun 30, 2025), down 8.3% from the prior quarter.

Analysis

Bright Minds Biosciences (DRUG) Receivables - Other (2022 - 2025) Analysis & Trends

At the end of FY2022 (ended Sep 30, 2022), Bright Minds Biosciences posted Receivables - Other of $32,321.

  • The fiscal Q3 2025 figure ranks as the lowest quarterly Receivables - Other since fiscal Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Bright Minds Biosciences 172.65 Mn -390.95 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 115,094.95
Mar 31, 2025 124,339.76
Mar 31, 2024 400,081.25
Sep 30, 2022 30,173.68
API Access

Bright Minds Biosciences Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=DRUG&period=max&api_key=YOUR_API_KEY